Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Change in Accured Expenses (2017 - 2024)

Solid Biosciences' Change in Accured Expenses history spans 8 years, with the latest figure at $1.6 million for Q4 2024.

  • For Q4 2024, Change in Accured Expenses rose 198.72% year-over-year to $1.6 million; the TTM value through Dec 2024 reached $4.8 million, up 168.41%, while the annual FY2024 figure was $4.8 million, 168.41% up from the prior year.
  • Change in Accured Expenses for Q4 2024 was $1.6 million at Solid Biosciences, down from $3.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.7 million in Q2 2022 and bottomed at -$5.0 million in Q3 2022.
  • The 5-year median for Change in Accured Expenses is -$341000.0 (2021), against an average of $10950.0.
  • The largest YoY upside for Change in Accured Expenses was 1515.01% in 2022 against a maximum downside of 1544.37% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $887000.0 in 2020, then surged by 190.42% to $2.6 million in 2021, then fell by 0.27% to $2.6 million in 2022, then tumbled by 164.03% to -$1.6 million in 2023, then skyrocketed by 198.72% to $1.6 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Change in Accured Expenses are $1.6 million (Q4 2024), $3.3 million (Q3 2024), and -$380000.0 (Q2 2024).